Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc (NASDAQ: ALXN) | World Leader in Treatments for Patients with Devastating and Rare Diseases.
Enterprise value
$39.0b
Share price
€15.55 ALXN
loading funding rounds…
CTI Life Sciences(exited)
OrbiMed(exited)
Connecticut Innovations(exited)
T. Rowe Price(exited)
BB Biotech(exited)
CHL Medical Partners(exited)
Zesiger Capital Group(exited)
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 16 % | 21 % | 22 % | 10 % | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | 59 % | 63 % | 63 % | 61 % | 60 % | 56 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 12 % | 2 % | 48 % | 10 % | 38 % | 38 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 23 % | 17 % | 17 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Alexion Pharmaceuticals
Edit
exited
ACQUISITION by Alexion Pharmaceuticals May 2015
ACQUISITION by Alexion Pharmaceuticals Jan 2011
ACQUISITION by Alexion Pharmaceuticals Dec 2011
ACQUISITION by Alexion Pharmaceuticals Oct 2019
ACQUISITION by Alexion Pharmaceuticals May 2020
ACQUISITION by Alexion Pharmaceuticals Apr 2018
ACQUISITION by Alexion Pharmaceuticals Oct 2022